Alkermes Inc., of Waltham, Mass., reported that its candidate for opioid induced bowel dysfunction (OBD), ALKS 37, significantly improved GI motility and increased frequency of bowel movements in a Phase II trial. The trial enrolled 87 patients with OBD who were randomized to receive escalating doses of ALKS 37, with the two highest doses showing the positive effects. The drug will be moved into a pivotal program in mid-2011.